Efficacy of Bifidobacterium Triple Live Capsules in the treatment of decompensated cirrhosis of hepatitis B virus infection and its influence on intestinal flora and liver fibrosis indexes
Objective To analyze the efficacy of Bifidobacterium Triple Live Capsules in the treatment of decompensated cirrhosis of hepatitis B virus(HBV)infection and the effects on intestinal flora and liver fibrosis indexes.Methods A total of 80 patients with decompensated HBV infection cirrhosis were randomly included and divided into combination group and control group,with 40 cases in each group,by using random number table method.The control group received conventional treatment combined with entecavir treatment,and the combined group received Bifidobacterium Triple Live Capsules treatment on the basis of the control group.The both groups were treated for 3 months.The clinical efficacy after 3 months of treatment,intestinal flora,liver fibrosis index,liver function and HBV deoxyribonucleotide(DNA)were compared between the 2 groups after 3 months of treatment,before and after 3 months of treatment,and the adverse reactions during treatment were also recorded and compared.Results After 3 months of treatment,the total effective rate of combination group was higher than that of control group(90.00%vs.70.00%,P<0.05).After 3 months of treatment,the levels of lactobacillus,bifidobacterium,and enterococcusin in combination group increased,and the combination group were higher than the control group(P<0.05);the levels of candida albicansin in combination group decreased,and the combination group was lower than the control group(P<0.05).After 3 months of treatment,the serum albumin(ALB)in the 2 groups increased,and the combination group was higher than the control group(P<0.05).After 3 months of treatment,the serum levels of hyaluronic acid(HA),laminin(LN),type Ⅲ procollagen(PC Ⅲ),type Ⅳ collagen(C Ⅳ),alanine aminotransferase(ALT),total bilirubin(TBiL),HBV deoxyribonucleotide(DNA)and liver hardness(LSM)in the 2 groups decreased,and the combination group was lower the combination group(P<0.05).During treatment,the incidence of adverse reactions was similar.Conclusion Bifidobacterium Triple Live Capsules have definite clinical efficacy in the treatment of decompensated cirrhosis of HBV infection.It could reduce HBV load,regulate intestinal flora balance,reduce liver fibrosis index,and finally improve liver function with good safety.
Bifidobacterium Triple Live Bacteria Capsulesentecavirhepatitis B virusdecompensation periodcirrhosis of the liverintestinal floraliver fibrosis
万方数据
维普
